nach oben

Current Infectious Disease Reports

Erschienen in:

01.04.2015 | Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Live Virus Vaccines in Transplantation: Friend or Foe?

verfasst von: Charlotte M. Verolet, Klara M. Posfay-Barbe

Erschienen in: Current Infectious Disease Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Solid organ and hematopoietic stem cell transplant recipients may be exposed to diseases which may be prevented through live attenuated virus vaccines (LAVV). Because of their immunosuppression, these diseases can lead to severe complications in transplant recipients. Despite increasing evidence regarding the safety and effectiveness of certain LAVV, these vaccines are still contraindicated for immunocompromised patients, such as transplant recipients. We review the available studies on LAVV, such as varicella zoster, measles–mumps–rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. We discuss the current recommendations and the potential risks, as well as the expected benefits of LAVV immunization in this population.

Stark K, Gunther M, Schonfeld C, et al. Immunisations in solid-organ transplant recipients. Lancet. 2002;359:957–65.PubMed

Wyplosz B, Van der Vliet D, Consigny PH, et al. Vaccinations for the traveling adult solid organ transplant recipient (excluding hematopoietic stem cell transplant recipients). Med Mal Infect. 2009;39:225–33.PubMed

Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J. 2012;12:228–43.PubMedCentralPubMed

Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25:101–16.PubMed

Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev. 1998;11:1–26.PubMedCentralPubMed

Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation. 2002;74:543–50.PubMed

Kumar D. Immunizations following solid-organ transplantation. Curr Opin Infect Dis. 2014;27:329–35.PubMed

8.••

Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18. Excellent updated review of the guidelines for vaccination of immunocompromised adults and children.PubMed

Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020–30.PubMed

10.

Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients†. Am J Transplant. 2010;10:18–25.PubMed

11.

Parham P. The immune system. Garland Science. 2009; third edition: 455.

12.

Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–65.PubMedCentralPubMed

13.

Plotkin SA. Vaccines, vaccination, and vaccinology. J Infect Dis. 2003;187:1349–59.PubMed

14.

Danziger-Isakov L, Evans HM, Green M, et al. Capacity building in pediatric transplant infectious diseases: an international perspective. Pediatr Transplant. 2014;18:790–3.PubMed

15.

Pittet LF, Posfay-Barbe KM. Immunization in transplantation: review of the recent literature. Curr Opin Organ Transplant. 2013;18(5):543–8.

16.

Lopez MJ, Thomas S. Immunization of children after solid organ transplantation. Pediatr Clin North Am. 2003;50:1435–49.PubMed

17.

Posfay-Barbe KM, Siegrist CA. Immunization and transplantation—what is new and what is coming? Pediatr Transplant. 2009;13:404–10.PubMed

18.

Diana A, Posfay-Barbe KM, Belli DC, et al. Vaccine-induced immunity in children after orthotopic liver transplantation: a 12-yr review of the Swiss national reference center. Pediatr Transplant. 2007;11:31–7.PubMed

19.

L'Huillier AG, Wildhaber BE, Belli DC, et al. Successful serology-based intervention to increase protection against vaccine-preventable diseases in liver-transplanted children: a 19-yr review of the Swiss national reference center. Pediatr Transplant. 2012;16:50–7.PubMed

20.

Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis. 2000;30:857–69.PubMed

21.

Sester M, Gartner BC, Girndt M, et al. Vaccination of the solid organ transplant recipient. Transplant Rev (Orlando). 2008;22:274–84.

22.

Danziger-Isakov L, Posfay-Barbe KM. Optimal approach to immunization in pediatric solid organ transplantation. Pediatr Transplant. 2012;16:680–3.PubMed

23.

Shinjoh M, Miyairi I, Hoshino K, et al. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2008;26:6859–63.PubMed

24.

Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521–6.PubMed

25.

Machado CM. Reimmunization after hematopoietic stem cell transplantation. Expert Rev Vaccines. 2005;4:219–28.PubMed

26.

Ariza-Heredia EJ, Gulbis AM, Stolar KR, et al. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014. doi:10.1111/tid.12312.

27.

Avery RK. Immunizations in adult immunocompromised patients: which to use and which to avoid. Cleve Clin J Med. 2001;68:337–48.PubMed

28.

Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992;9:427–32.PubMed

29.

Sauerbrei A, Prager J, Hengst U, et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997;20:381–3.PubMed

30.

Styczynski J, Gil L, Party EPDW. Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant. 2008;42 Suppl 2:S77–81.PubMed

31.

Inaba H, Hartford CM, Pei D, et al. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2012;156:109–17.PubMedCentralPubMed

32.

Danziger-Isakov L, Kumar D, Practice ASTIDCo. Vaccination in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:311–7.PubMed

33.••

Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12:2974–85. A significant interventional study which measured both humoral and cell-mediated immunity to VZV immunization in pediatric liver transplant recipients.PubMed

34.

Office fédéral de la santé publique. Vaccination contre la varicelle. Recommandations dela Commission suisse pour les vaccinations (CSV) et de l’Office fédéral de la santé publique (OFSP). Bull OFSP. 2004;45:846–8.

35.

Feldhoff CM, Balfour Jr HH, Simmons RL, et al. Varicella in children with renal transplants. J Pediatr. 1981;98:25–31.PubMed

36.

Geel A, Zuidema W, van Gelder T, et al. Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc. 2005;37:952–3.PubMed

37.

Fehr T, Bossart W, Wahl C, et al. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation. 2002;73:608–11.PubMed

38.

Furth SL, Neu AM, Sullivan EK, et al. Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1997;11:443–6.PubMed

39.

McGregor RS, Zitelli BJ, Urbach AH, et al. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics. 1989;83:256–61.PubMed

40.

Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol. 2004;25:603–8.PubMed

41.

Banovic T, Yanilla M, Simmons R, et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis. 2011;204:1893–901.PubMed

42.

Prelog M, Zimmerhackl LB. Varicella vaccination in pediatric kidney and liver transplantation. Pediatr Transplant. 2010;14:41–7.PubMed

43.

Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics. 1997;99:35–9.PubMed

44.

Mizuta K, Urahashi T, Ihara Y, et al. Varicella zoster virus disease after pediatric living donor liver transplantation: is it serious? Transplant Proc. 2012;44:780–3.PubMed

45.

Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol. 2006;142:943–5.PubMed

46.

Levitsky J, Te HS, Faust TW, et al. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant. 2002;2:880–2.PubMed

47.

Kotton CN. Immunization after kidney transplantation—what is necessary and what is safe? Nat Rev Nephrol. 2014;10(10):555–62.PubMed

48.

Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6:565–8.PubMed

49.

Zamora I, Simon JM, Da Silva ME, et al. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol. 1994;8:190–2.PubMed

50.

Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant. 2005;9:192–6.PubMed

51.

Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10:78–82.PubMed

52.

Ljungman P, Wang FZ, Nilsson C, et al. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer. 2003;11:739–41.PubMed

53.•

Sasadeusz J, Prince HM, Schwarer A, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014. doi:10.1111/tid.12295. An interesting interventional study showing that the VZV vaccine is safe but not immunogenic when administered early after HSCT.PubMed

54.

Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17:1708–13.PubMedCentralPubMed

55.

Kussmaul SC, Horn BN, Dvorak CC, et al. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010;45:1602–6.PubMed

56.

Bhalla P, Forrest GN, Gershon M, et al. Disseminated persistent and fatal infection due to the vaccine strain (vOka) of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis. 2014; ciu970.

57.

Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–85.PubMed

58.

Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008;8:9–14.PubMed

59.

Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87:123–5.PubMed

60.•

Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20:285–7. A large interventional study looking at the Herpes Zoster vaccine immunization in HSCT patients.PubMed

61.

Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26–34.PubMed

62.

Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176:578–85.PubMed

63.

Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–9.PubMedCentralPubMed

64.

Kalman S, Bakkaloglu SA, Ozkaya O, et al. Measles: a rare communicable disease in a child with renal transplantation. Pediatr Transplant. 2002;6:432–4.PubMed

65.

Gastanaduy PA, Redd SB, Fiebelkorn AP, et al. Measles—United States, January 1-May 23, 2014. MMWR Morb Mortal Wkly Rep. 2014;63:496–9.PubMed

66.

National Center for Immunization and Respiratory Diseases DoVD, Division of Viral Diseases. Measles cases and outbreaks. 2015. Available at: http://www.cdc.gov/measles/cases-outbreaks.html

67.

Kidd IM, Booth CJ, Rigden SP, et al. Measles-associated encephalitis in children with renal transplants: a predictable effect of waning herd immunity? Lancet. 2003;362:832.PubMed

68.

Sternfeld T, Spori-Byrtus V, Riediger C, et al. Acute measles infection triggering an episode of liver transplant rejection. Int J Infect Dis. 2010;14:e528–30.PubMed

69.

Young MK, Nimmo GR, Cripps AW, et al. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014;4, CD010056.PubMed

70.

Baas MC, van Donselaar KA, Florquin S, et al. Mumps: not an innocent bystander in solid organ transplantation. Am J Transplant. 2009;9:2186–9.PubMed

71.

Mazariegos GV, Green M, Reyes J, et al. Rubella infection after orthotopic liver transplantation. Pediatr Infect Dis J. 1994;13:161–2.PubMedCentralPubMed

72.

Eyre TA, Pelosi E, McQuaid S, et al. Mumps virus encephalomyelitis in a 19-year old male patient with an undefined severe combined immunodeficiency post-haematopoietic bone marrow transplantation: a rare fatal complication. J Clin Virol. 2013;57:165–8.PubMed

73.

Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant. 2005;9:652–61.PubMed

74.

Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123:87–9.PubMed

75.

Machado CM, Goncalves FB, Pannuti CS, et al. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood. 2002;99:83–7.PubMed

76.

Machado CM, de Souza VA, Sumita LM, et al. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35:787–91.PubMed

77.

Shaw PJ, Bleakley M, Burgess M. Safety of early immunization against measles/mumps/rubella after bone marrow transplantation. Blood. 2002;99:3486.PubMed

78.

Pauksen K, Linde A, Lonnerholm G, et al. Influence of the specific T cell response on seroconversion after measles vaccination in autologous bone marrow transplant patients. Bone Marrow Transplant. 1996;18:969–73.PubMed

79.

Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012;17:601–8.PubMed

80.••

Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses. 2013;7 Suppl 3:60–6. An excellent update on influenza's epidemiology, prevention through immunization, and antiviral prophylaxis and treatment in immunocompromised patients.PubMed

81.

Manuel O, Humar A, Berutto C, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant. 2011;30:679–84.PubMed

82.

Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant. 2007;7:2567–72.PubMed

83.

Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis. 2006;17:206–12.PubMed

84.

Office fédéral de la santé publique, Commission fédérale pour les vaccinations (CFV), Groupe de travail Influenza (GTI). Directives et recommandations. Recommandations pour la vaccination contre la grippe. Berne: Office Fédéral de la Santé Publique, 2011.

85.

Moore DL, Canadian Paediatric Society ID. Immunization C. Vaccine recommendations for children and youth for the 2014/2015 influenza season. Paediatr Child Health. 2014;19:440–4.PubMedCentralPubMed

86.

Committee On Infectious D, Committee On Infectious D. Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics. 2014;134:e1503–19.

87.

Abuali MM, Arnon R, Posada R. An update on immunizations before and after transplantation in the pediatric solid organ transplant recipient. Pediatr Transplant. 2011;15:770–7.PubMed

88.

Vermeiren P, Aubert V, Sugamele R, et al. Influenza vaccination and humoral alloimmunity in solid organ transplant recipients. Transpl Int. 2014;27:903–8.PubMed

89.

Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. 2009;9:2346–54.PubMed

90.

Gowda R, Cartwright K, Bremner JA, et al. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol. 2004;72:299–301.PubMed

91.

Slifka MK, Hammarlund E, Lewis MW, et al. Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. Transplantation. 2013;95:e59–61.PubMedCentralPubMed

92.

Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2014;S1386–6532(14):00369–2.

93.

Gerasimon G, Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J. 2005;98:653–6.PubMed

94.

Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91–7.PubMed

95.

Yax JA, Farnon EC, Cary EN. Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow fever vaccine. J Travel Med. 2009;16:365–7.PubMed

96.

Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;1, CD010929.PubMed

97.

Pistone T, Verdiere CH, Receveur MC, et al. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res. 2010;8:461–6.PubMed

98.

Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85:131–4.PubMed

99.

Azevedo LS, Lasmar EP, Contieri FL, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14:237–41.PubMed

100.

Who. Polio vaccines: WHO position paper, January 2014—recommendations. Vaccine. 2014;32:4117–8.

101.

Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–22. quiz CE21-27.PubMed

102.

Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum Vaccine Immunother. 2014;10:263–79.

103.

Organization WH. Japanese encephalitis surveillance and immunization—Asia and the western Pacific 2012. MMWR Morb Mortal Wkly Rep. 2013;62:658–62.

104.

Griffiths MJ, Turtle L, Solomon T. Japanese encephalitis virus infection. Handb Clin Neurol. 2014;123:561–76.PubMed

105.

Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet. 1996;347:1583–6.PubMed

106.

Tsai TF, Yu YX, Jia LL, et al. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine—a comparison of 1- and 3-month immunization schedules. J Infect Dis. 1998;177:221–3.PubMed

107.•

Pakakasama S, Wattanatitan S, Techasaensiri C, et al. Immunogenicity of a live-attenuated Japanese encephalitis vaccine in children and adolescents after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49:1307–9. The first interventional study on JE (SA 14-14-12) immunization in transplant patients.PubMed

108.

Lerchenfeldt SM, Cronin SM, Chandrasekar PH. Vaccination adherence in hematopoietic stem cell transplant patients: a pilot study on the impact of vaccination cards and reminder telephone calls. Transpl Infect Dis. 2013;15:634–8.PubMed

109.

Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159:610–5.PubMed

110.

King SM, Saunders EF, Petric M, et al. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant. 1996;17:633–6.PubMed

Titel: Live Virus Vaccines in Transplantation: Friend or Foe?
verfasst von: Charlotte M. Verolet
Klara M. Posfay-Barbe
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 4/2015
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-015-0472-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

What We Know and What We Do Not Know About Factors Associated with and Interventions to Promote Antiretroviral Adherence

Value of Solid Organ Transplant-Trained Pharmacists in Transplant Infectious Diseases

The Challenges and Promise of HIV-Infected Donors for Solid Organ Transplantation

Hand Hygiene Compliance Monitoring: the State of the Art

Imaging in Neurologic Infections II: Fungal and Viral Diseases